Oragenics (NYSEAMERICAN:OGEN) Posts Earnings Results

Oragenics (NYSEAMERICAN:OGEN) posted its earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, FiscalAI reports.

Oragenics Stock Performance

OGEN traded down $0.01 during midday trading on Thursday, reaching $0.53. 4,702 shares of the company were exchanged, compared to its average volume of 239,168. The company’s fifty day moving average price is $0.56 and its 200 day moving average price is $0.64. The company has a market cap of $2.39 million, a price-to-earnings ratio of -0.02 and a beta of 1.24. Oragenics has a one year low of $0.48 and a one year high of $1.45.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OGEN. DRW Securities LLC boosted its position in shares of Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after buying an additional 50,900 shares during the last quarter. XTX Topco Ltd purchased a new stake in Oragenics in the 4th quarter valued at $26,000. Finally, Bank of America Corp DE raised its position in Oragenics by 7,374.0% in the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after buying an additional 15,338 shares during the last quarter. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.